CIK 0001133416 · Non-accelerated filer<br>Smaller reporting company
GALECTIN THERAPEUTICS INC
Sign in to watch- Ticker
- GALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 043562325
- Phone
- 678-620-3186
- Business address
- 4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA, 30071
- Former names
- PRO PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-16 | CALLICUTT JACK W Chief Financial Officer | Grant or award · Restricted Stock Unit 10b5-1 | +100,000 | 100,000 | ||
| 2026-01-16 | Shlevin Harold H. Director | Grant or award · Stock option (right to buy) | +60,000 | 60,000 | ||
| 2026-01-16 | OMENN GILBERT S Director | Grant or award · Stock option (right to buy) | +60,000 | 60,000 | ||
| 2026-01-16 | AMELIO GILBERT F Director | Grant or award · Stock option (right to buy) | +60,000 | 60,000 | ||
| 2026-01-16 | Schwartz Elissa J. Director | Grant or award · Stock option (right to buy) | +60,000 | 60,000 | ||
| 2026-01-16 | Uihlein Richard E Director | Grant or award | +13,158 | $3.04 | $40K | 10,332,676 |
| 2026-01-16 | Uihlein Richard E Director | Grant or award · Stock option (right to buy) | +60,000 | 60,000 | ||
| 2026-01-06 | LEWIS JOEL President and CEO | Sale 10b5-1 | −37,698 | $3.58 | $135K | 832,592 |
| 2026-01-06 | CALLICUTT JACK W Chief Financial Officer | Sale 10b5-1 | −20,354 | $3.67 | $75K | 7,614 |
| 2026-01-06 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −21,446 | $3.65 | $78K | 0 |
| 2026-01-05 | LEWIS JOEL President and CEO | Other disposition 10b5-1 | −56,332 | $3.88 | $219K | 776,260 |
| 2026-01-05 | LEWIS JOEL President and CEO | Sale 10b5-1 | −27,731 | $3.91 | $108K | 870,290 |
| 2026-01-05 | CALLICUTT JACK W Chief Financial Officer | Sale 10b5-1 | −25,732 | $3.90 | $100K | 27,968 |
| 2026-01-05 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −25,499 | $3.90 | $99K | 21,446 |
| 2026-01-02 | LEWIS JOEL President and CEO | Option exercise 10b5-1 | +84,000 | 916,592 | ||
| 2026-01-02 | LEWIS JOEL President and CEO | Sale 10b5-1 | −18,571 | $4.20 | $78K | 898,021 |
| 2026-01-02 | LEWIS JOEL President and CEO | Option exercise · Restricted Stock Unit 10b5-1 | −84,000 | 0 | ||
| 2026-01-02 | CALLICUTT JACK W Chief Financial Officer | Option exercise 10b5-1 | +60,000 | 67,614 | ||
| 2026-01-02 | CALLICUTT JACK W Chief Financial Officer | Sale 10b5-1 | −13,914 | $4.20 | $58K | 53,700 |
| 2026-01-02 | Jamil Khurram Chief Medical Officer | Option exercise 10b5-1 | +60,000 | 60,000 |
Page 3 of 15 · 291 trades